- Title
- Phase 2, randomized, 3-arm study of abiraterone acetate and prednisone (AAP), AAP plus degarelix (AAP+D), and degarelix (D) alone for patients (pts) with biochemically-recurrent prostate cancer (PC) following radical prostatectomy (RP)
- Creators
- Karen A. Autio - Memorial Sloan Kettering Cancer CenterEmmanuel S. Antonarakis - Sidney Kimmel Comprehensive Cancer CenterTina M. Mayer - Rutgers Cancer InstituteUlka N. Vaishampayan - The Barbara Ann Karmanos Cancer InstituteDaniel H. Shevrin - NorthShore University HealthSystemMichael Roger Harrison - Duke Medical CenterScott T. Tagawa - Sandra and Edward Meyer Cancer Center, New York, NYMatthew I. Milowsky - University of North Carolina Health CareJulie Nicole Graff - VA Portland Health Care SystemTomasz M. Beer - Oregon Health & Science UniversityLuke T. Nordquist - Urology Cancer Center and GU Research Networket al.
- Publication Details
- Journal of clinical oncology, Vol.36(15_suppl), pp.5016-5016
- Number of pages
- 1
- Identifiers
- 991006262304602656
- Academic Unit
- Radiology
- Language
- English
- Resource Type
- Journal article
Journal article
Phase 2, randomized, 3-arm study of abiraterone acetate and prednisone (AAP), AAP plus degarelix (AAP+D), and degarelix (D) alone for patients (pts) with biochemically-recurrent prostate cancer (PC) following radical prostatectomy (RP)
Journal of clinical oncology, Vol.36(15_suppl), pp.5016-5016
05/20/2018
Metrics
1 Record Views